Recruitment

Recruitment Status
Completed

Inclusion Criteria

Diagnosis of open angle glaucoma or ocular hypertension including pigment dispersion glaucoma and pseudoexfoliation glaucoma.
Age ≥ 18 years, of either gender, or any race/ethnicity
Diagnosis of open angle glaucoma or ocular hypertension including pigment dispersion glaucoma and pseudoexfoliation glaucoma.
Age ≥ 18 years, of either gender, or any race/ethnicity

Exclusion Criteria

History of allergy or intolerance to topical carbonic anhydrase inhibitors, or alpha-agonists
Females who are currently pregnant or planning to become pregnant during the study period
Patients currently taking oral beta blocker therapy
...
History of allergy or intolerance to topical carbonic anhydrase inhibitors, or alpha-agonists
Females who are currently pregnant or planning to become pregnant during the study period
Patients currently taking oral beta blocker therapy
Patients who smoke or have irregular daily sleep patterns
Patients who have started or changed glucocorticoids therapy in the last 3 months
Diagnosis of any other form of glaucoma other than open-angle
Patients who are currently using medical or recreational marijuana
Intraocular surgery within 6 months or laser within 3 months
Inability to safely discontinue all ocular medications for 6 weeks
Contraindications to beta blockers (see below)
Any use of a non-FDA approved medication for glaucoma in the last 3 months
Schaffer angle grade < 2 in either eye by gonioscopy

Summary

Conditions
  • Ocular Hypertension
  • Open Angle Glaucoma
  • Pigment Dispersion Syndrome
  • Pseudoexfoliation Glaucoma
Type
Observational
Design
  • Observational Model: Cohort
  • Time Perspective: Prospective

Participation Requirements

Age
Between 18 years and 125 years
Gender
Both males and females

Description

Intraocular pressure (IOP) is a major risk factor for the development of glaucoma. In addition, it is the only modifiable factor in the prevention and subsequent treatment of glaucomatous optic neuropathy. Most clinicians only have access to a single IOP measurement during a patient visit that may o...

Intraocular pressure (IOP) is a major risk factor for the development of glaucoma. In addition, it is the only modifiable factor in the prevention and subsequent treatment of glaucomatous optic neuropathy. Most clinicians only have access to a single IOP measurement during a patient visit that may only occur once every four months. These snapshots in time are probably not adequate for the optimal management of glaucoma. Diurnal IOP curves can provide a better estimate of each patient's individual IOP variation throughout the day. However diurnal curves do not typically cover another crucial time, the nocturnal period. Glaucomatous eyes have been shown to have different IOP curves during the nocturnal period compared to healthy controls. In addition, different classes of glaucoma drugs have variable IOP lowering effects during the nocturnal hours compared to the diurnal/wake period. For example, the betablocker timolol was shown to lower IOP during daytime hours but failed to lower IOP during the nocturnal period in the habitual position. Similarly, the alpha-agonist brimonidine failed to lower IOP overnight after significantly lowering IOP during the diurnal period. On the other hand, the prostaglandin analogues, including latanoprost and travoprost, lowered IOP throughout the diurnal and nocturnal periods although nocturnal lowering appears less than the daytime hours. Therefore it is crucial to determine an accurate IOP curve for each form of medication during both wake and sleep hours.

Inclusion Criteria

Diagnosis of open angle glaucoma or ocular hypertension including pigment dispersion glaucoma and pseudoexfoliation glaucoma.
Age ≥ 18 years, of either gender, or any race/ethnicity
Diagnosis of open angle glaucoma or ocular hypertension including pigment dispersion glaucoma and pseudoexfoliation glaucoma.
Age ≥ 18 years, of either gender, or any race/ethnicity

Exclusion Criteria

History of allergy or intolerance to topical carbonic anhydrase inhibitors, or alpha-agonists
Females who are currently pregnant or planning to become pregnant during the study period
Patients currently taking oral beta blocker therapy
...
History of allergy or intolerance to topical carbonic anhydrase inhibitors, or alpha-agonists
Females who are currently pregnant or planning to become pregnant during the study period
Patients currently taking oral beta blocker therapy
Patients who smoke or have irregular daily sleep patterns
Patients who have started or changed glucocorticoids therapy in the last 3 months
Diagnosis of any other form of glaucoma other than open-angle
Patients who are currently using medical or recreational marijuana
Intraocular surgery within 6 months or laser within 3 months
Inability to safely discontinue all ocular medications for 6 weeks
Contraindications to beta blockers (see below)
Any use of a non-FDA approved medication for glaucoma in the last 3 months
Schaffer angle grade < 2 in either eye by gonioscopy

Tracking Information

NCT #
NCT02165631
Collaborators
Not Provided
Investigators
  • Principal Investigator: Malik Y Kahook, MD University of Colorado, Denver
  • Malik Y Kahook, MD University of Colorado, Denver
About Us
Innovation
Privacy
Terms
Copyright
Get Well Soon © Copyright 2024